Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NYM032 PET/CT in Newly Diagnosed Prostate Cancer
NCT07615101Phase 3Recruiting
- Sponsor
- Norroy Bioscience
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 68Ga-NYM032 in prostate cancer (PCa), sponsored by Norroy Bioscience. Primary endpoint: Diagnostic Sensitivity and Specificity at 30 days. Started Aug 2026; status: recruiting.
02
Drugs
68Ga-NYM032
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07615101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615101.